

Cite this: *RSC Adv.*, 2018, **8**, 36675

A novel information diffusion method based on network consistency for identifying disease related microRNAs

Min Chen, ^{†ab} Yan Peng, ^{†c} Ang Li, ^{*a} Zejun Li, ^{ab} Yingwei Deng, ^a Wenhua Liu, ^a Bo Liao ^{*b} and Chengqiu Dai^a

The abnormal expression of miRNAs is directly related to the development of human diseases. Predicting the potential candidate miRNAs associated with diseases can contribute to the detection, diagnosis, treatment and prevention of human complex diseases. The effective inference of the calculation method of the relationship between miRNAs and diseases is an effective supplement to biological experiments. It is of great help in the prevention, treatment and prognosis of complex diseases. This paper proposes a novel information diffusion method based on network consistency (IDNC) for identifying disease related microRNAs. The model first synthesizes the miRNA family information and the miRNA function similarity to reconstruct the miRNA network, and reconstruct the disease network by using the known disease and miRNA-related information and the semantic score between diseases. Then the global similarity of the two networks is obtained by using the Laplacian score of graphs. The global similarity score is a measure of the similarity between diseases and miRNAs. The disease–miRNA relation network was reconstructed by integrating the global similarity relation. The network consistency diffusion seed is then obtained by combining the global similarity network with the reconstructed disease–miRNA association network. Thereafter, the stable diffusion spectrum is generated as the prediction score by using the restarted random walk algorithm. The AUC value obtained by performing the LOOCV in the gold benchmark dataset is 0.8814. The AUC value obtained by performing the LOOCV in the predictive dataset is 0.9512. Compared with other frontier methods, our method has higher accuracy, which is further illustrated by case studies of breast neoplasms and colon neoplasms to prove that IDNC is valuable.

Received 9th September 2018
Accepted 17th October 2018

DOI: 10.1039/c8ra07519k
rsc.li/rsc-advances

Introduction

RNA is the intermediate between DNA and encoded protein. It has a variety of important functions and is ubiquitous in organisms. The RNA that is not involved in the process of encoding protein is called non-coding RNA. About 98% of the human genome sequences are non-coding regions.¹ miRNA means the single-strand endogenous non-coding RNA with a length of about 20–25 nucleotides and is evolutionarily conserved. miRNAs are widely distributed in eukaryotes. In human genes, the number of miRNAs can account for 1–4%^{2–5} of the total. The discovery of miRNA has been initially considered and has not received much attention. However, in

recent years, there has been increasing evidence that shows the correlation between miRNAs and many life processes, such as cell growth,^{6,7} tissue differentiation,⁸ cell proliferation,⁹ embryonic development,¹⁰ apoptosis,¹¹ metabolism^{12,13} and so on.

Recently, miRNAs have been found to be closely related to human tumors, especially the changes in the expression of miRNAs are involved in the occurrence, progression and metastasis of various types of human cancer.¹⁴ For example, hsa-mir-10b is unregulated in breast neoplasms compared with benign breast lesions;¹⁵ hsa-mir-126 and hsa-mir-145 can inhibit the growth of colonic tumor cells;^{16,17} hsa-mir-21 has higher expression level in colon cancer cells;¹⁸ Gao *et al.*¹⁹ found that the expression of hsa-mir-155 in serum of lung cancer patients was much higher than that of normal samples by PCR test; Johnson²⁰ found that the down regulation of the let-7 family led to the development of lung cancer.

The identification of disease-related miRNAs is of great importance to human health. Identifying the interaction between miRNAs and diseases have become a key issue. Many researchers have worked hard to identify the interaction. The association between miRNAs and diseases can be accurately

^aCollege of Computer Science and Technology, Hunan Institute of Technology, 421002 Hengyang, China. E-mail: liang@hnit.edu.cn

^bCollege of Information Science and Engineering, Hunan University, Changsha 410082, China. E-mail: dragonbw@163.com

^cCollege of International Communication, Hunan Institute of Technology, 421002 Hengyang, China

† The authors wish it to be known that, in their opinion, the first two authors should be regarded as joint first authors.

mined through sophisticated biological experiments but it is subject to high cost, long experimental period, and high requirements on equipment.^{21–24} In recent years, with the discovery of a large number of miRNAs, researchers have developed a variety of databases to store related information about miRNAs. With these data as the background, more and more bioinformatics calculation methods have been developed to predict their relationship.^{25–30} This kind of calculation method is the best supplement to biological experiments. The advantages include reducing the blindness of biologists' biological experiments, reducing the cost of biological experiments, and saving the human and material resources of biological experiments. At present, this method can be roughly divided into machine learning method and biological network method.^{31–33} The methods of predicting disease-associated miRNA are elaborated below from these two aspects.

In 2010, Jiang *et al.*³⁴ extracted positive sample data from negative sample data by using support vector machine. The method extracted features from miRNA target data and phenotypic similarity data, which achieved good prediction results. In 2011, Xu *et al.*³⁵ took prostate cancer as an example and proposed an MTDN calculation method to predict prostate cancer related miRNA by using miRNA target topology imbalance network. In 2016, Zeng *et al.*³⁶ adopted two multipath methods to predict the association between miRNA and disease. All of these methods require the negative sample information of known disease-related miRNA, while negative miRNA–disease association is hard to obtain.

In 2014, Chen *et al.* proposed a regularized least squares semi supervised algorithm (RLSMDA) to predict potential miRNA–disease association.³⁷ This method is built on semi supervised learning framework to predict potential disease–miRNA association and does not require related negative miRNA–disease information. In 2017, Chen *et al.*³⁸ proposed LRSSLMDA model to predict miRNA–disease association with Laplacian Regularized Sparse Subspace Learning. In 2017, Peng *et al.*³⁹ proposed a new information fusion strategy RLSSLP based on the regularization framework and the idea of Kronecker's regularized least squares based on multi-core learning. In 2017, Chen *et al.*⁴⁰ established a MKRMDA model that can automatically optimize the combination of disease and miRNA multi-source data and efficiently use multi-core data to predict the potential association of miRNA–diseases. In 2017, Luo *et al.*⁴¹ used Kronecker regularized least squares to predict miRNA related diseases based on heterogeneous omics data.

Matrix factorization is designed to predict the association between disease and miRNA.⁴² In 2016, Lan *et al.*⁴³ proposed a computational model kbmf-md to predict the association between miRNA and disease based on the improved microRNA and disease similarities. In 2016, Lan *et al.*⁴⁴ used nuclear Bayesian matrix factorization to forecast potential miRNA–disease association. In 2018, Xiao *et al.*⁴⁵ integrated the semantic information of diseases with the functional information of the miRNA to obtain the isomeric data, and then used the isomeric data to regularize the non-negative matrix factorization of the graph to predict the potential association between miRNA and the disease, which is called GRNMF. In 2018, Zhong

*et al.*⁴⁶ constructed a double layer network to express the complex relationship between miRNA, disease and miRNA–disease, and then sorted out the non-negative matrix factorization method to predict the potential disease miRNA. In 2018, Chen *et al.*⁴⁷ developed a computational model of matrix decomposition and heterogeneous graph inference for miRNA–disease association prediction.

In addition, neural network and other algorithms are designed to predict the association between disease and miRNA. In 2017, Chen *et al.*⁴⁸ proposed model EGBMMDA based on the relationship between Extreme Gradient Boosting Machine to predict association between miRNA and disease. In 2017, Chen *et al.*⁴⁹ developed a miRNA–disease association prediction model DRMDA based on depth representation. After data extraction and depth representation, the unsupervised hierarchical layer-by-layer greedy pre-training and Support Vector Machine were used to predict the miRNA–disease association. In 2017, Fu *et al.*⁵⁰ proposed a deep integration model, DeepMDA, which used an automatic encoder to extract advanced features from similar information, and then used a three layer neural network to predict the association between miRNAs and diseases. In 2015, Chen *et al.*⁵¹ used a Restricted Boltzmann Machine (RBM) to predict different types of miRNA–disease associations by applying RBMMDA method. In 2017, Luo *et al.*⁵² developed a predictive method CPTL based on transduction learning.

However, previous studies are not adequate and have some disadvantages, such as the lack of miRNAs similarity data and the facts that known relationship between miRNAs and diseases is scarce and that there are few negative samples. In 2016, Zeng *et al.*⁵³ proposed a method to predict miRNA–disease association by matrix completion algorithm based on miRNA–miRNA network and disease–disease network. In 2017, Li *et al.*⁵⁴ propose MCMDA method to predict miRNA–disease association by using matrix completion algorithm. In 2017, Peng *et al.*⁵⁵ used the improved low rank matrix recovery (ILRMR) algorithm to predict the correlation between miRNAs and diseases. In this method, it is possible to predict diseases which are not associated with any known miRNA. In 2018, Chen *et al.*⁵⁶ presents a novel model of inductive matrix completion for miRNA–disease association prediction. Zhao *et al.*⁵⁷ used symmetric nonnegative matrix factorization to reveal the relation of miRNA–disease pairs.

Bioinformatics researchers also utilized recommendation system.⁵⁸ In 2014, Li *et al.*⁵⁹ developed a computational system toxicology framework which used the recommendation system to predict the new association of environmental factors, miRNA and diseases by integrating the structural similarity of environmental factors and the phenotype similarity of diseases. In 2017, Gu *et al.*⁶⁰ applies collaborative filtering recommendation algorithms to the miRNA–disease association prediction. In 2017, Peng *et al.*⁶¹ combined rating-based recommendation algorithm with negative-aware algorithm to predict miRNA–disease association. In 2017, Chen *et al.*⁶² proposed a new computational model HAMDA for miRNA–disease association by using hybrid graph-based



recommendation algorithm. HAMDA not only considered the network structure and information dissemination, but also discussed the problem of node assignment. A satisfactory prediction result was achieved.

In 2015, inspired by social network analysis, Zou *et al.*⁶³ proposed to using the methods based on social network analysis for the prediction of miRNA–disease association. They used two social network analysis methods, KATZ and CATAPULT, to analyze heterogeneous networks. CATAPULT is a deformation of supervised learning algorithm and can overcome the shortcoming that there are only positive samples and unmarked samples in miRNA–disease association. In 2018, Chen *et al.*⁶⁴ proposed a computational model of Ensemble Learning and Link Prediction for miRNA–disease association prediction.

Based on the hypothesis, that functionally related miRNA tends to associate with phenotypically similar diseases, many calculation methods have been proposed to predict the potential association between miRNA and disease.^{25–27}

In 2009, Jiang *et al.*⁶⁵ first proposed a hypergeometric distribution model to predict miRNA–disease correlation. In 2010, Jiang *et al.*⁶⁶ proposed a new method based on genomic data integration, integrating a variety of data resources with naive Bayes model and establishing a functional prediction model among genes. In 2011, Li *et al.* put forward a method of genes' functional consistency to predict carcinogenic miRNA.⁶⁷ In 2013, Shi *et al.* further proposed a computational model that exploits the functional association between miRNAs and diseases.⁶⁸ They integrated the disease–target association, the known disease–gene association, the protein inter-association to create a complex network. Then they made use of the random walk algorithm on the network and achieved a good prediction effect. In 2014, Xu *et al.*⁶⁹ proposed a disease-associated miRNA prediction method which integrated the phenotypically similar miRNAs with mRNAs expression profiles. However, these methods depend on the prediction of miRNA–target association, and the false positive of the target gene is high. So they cannot obtain high predictive performance.

In 2011, Rossi *et al.*⁷⁰ proposed a method called OMiR to predict the association of diseases in miRNA and OMIM. They calculated the degree of overlap between miRNA loci and disease loci in OMIM as the correlation between miRNA and disease. Xuan *et al.* proposed a prediction method based on weighted k most similar neighbors, which is called HDMP.⁷¹ However, HDMP cannot be applied to the prediction of isolated diseases. In 2017, Chen *et al.*⁷² designed a novel KNN-based disease-related sorting algorithm (RKNNMDA). In 2015, Le *et al.*⁷³ used PageRank and k -step Markov algorithm, a classic algorithm for web page ranking in link analysis to predict the association between disease and miRNAs.

In 2012, Chen *et al.*⁷⁴ proposed a RWRMDA computing model based on the similarity of global networks to predict the miRNA–disease association. They utilized the restarted random walk method to predict the pathogenetic miRNA. The results demonstrated that the global similarity network can improve the prediction accuracy more than the local similarity network. However, this method cannot predict new diseases

without any known association. In 2013 and 2016, Shi^{68,75} integrated data such as protein–protein and gene ontology data to build heterogeneous networks where the random walk algorithm can also be employed to predict. In 2015, Xuan *et al.*⁷⁶ designed a computing model named MIDP based on random walk algorithm. In 2015, Liao *et al.*⁷⁷ designed a global similarity prediction model based on information diffusion, which is known as NDBM. In 2017, Luo *et al.*⁷⁸ implemented the unbalanced bi-random walk algorithm (BRWH) on heterogeneous networks to search two-part graph sub-graphs to discover potential miRNA–disease associations. In 2017, Mugunga *et al.*⁷⁹ combined the path-based features and the random walk algorithm to predict the association between miRNA and disease.

In 2013, Chen *et al.* proposed Net-CBI method to predict the relationship between miRNA and disease by using the consistency of disease network.⁸⁰ In 2016, Gu *et al.*⁸¹ designed a network consistency method to predict miRNA–disease association (NCPMDA). In 2017, Li *et al.*⁸² proposed an integrated network similarity method (NSIM).

In 2015, Nalluri *et al.*⁸³ designed two scientific methods from the perspective of graph theory: one is to choose the maximum weighted matching inference model of the dominant disease by solving an equation; the other is based on the model of motivation analysis. In 2016, Chen *et al.*⁸⁴ constructed a heterogeneous graph method to predict miRNA–disease association method, which is called HGIMDA. In 2017, You *et al.*⁸⁵ proposed A novel and effective path-based miRNA–disease association prediction method, PBMDA, which uses a unique depth-first search algorithm to search in the isomeric graph. In 2016, Sun *et al.*⁸⁶ proposed a method to predict the association between them by using network topological similarity of miRNA–disease correlation network, which is called NTSMDA. In 2018, Chen *et al.*⁸⁷ proposed a novel computational model of triple layer heterogeneous network based inference for miRNA–disease association prediction. Chen *et al.*⁸⁸ proposed a method of graph regression to predict the miRNA–disease association.

In 2016, Chen *et al.*⁸⁹ developed the model of within and between score to predict potential miRNAs associated with various complex diseases. In 2017, Chen *et al.*⁹⁰ used the graphlet interaction of miRNAs (diseases) to represent the complex relationship between any two miRNAs (diseases), and established a GIMDA model for predicting the potential miRNA–diseases association by calculating the number of interactions of different types. In 2017, Chen *et al.*⁹¹ introduced the concepts of “super miRNA” and “super disease” to strengthen the similarity measurement of disease and miRNA. In 2018, Li *et al.*⁹² present a label propagation model with linear neighborhood similarity to predict unobserved miRNA–disease associations.

To sum up, due to the complexity of biological systems and the limitations of existing research methods, some problems and challenges exist in the field of disease–miRNA association prediction: firstly, the prediction accuracy is not high; secondly, many algorithms isolate disease and new miRNA prediction without known association; thirdly, the method of



similarity construction is not reasonable in most of the current models; the fourth is the problem of model defects. At present, many machine-learning methods either need negative samples or have difficulties in model training. Some methods based on biological networks use local information instead of global information, which results in poor prediction accuracy. Many methods have data dependence problem. The generalization ability of some methods is not strong. Some methods have good prediction ability for a data set but not satisfactory for other data sets. It is urgent to develop simple, effective and universal models for disease-related miRNA prediction.

In view of the shortcomings of the algorithm described above, we designed an information diffusion disease association prediction method based on network consistency to reveal the potential relationship between miRNA and disease. On the basis of building disease and miRNA global similarity network, this method reconstructs two disease-miRNA association networks. By using the consistency of the network to capture the comprehensive information of the vector, the information diffusion method is used to forecast the correlation. The experimental results show that the proposed method has some advantages: no need for negative samples; the ability to predict isolated disease and new miRNA, the simple design of the algorithm and so on. In the comparison of methods, our method is superior to other methods on different data sets, and case studies show better prediction ability of the algorithm.

Materials and methods

Data preparation

We first downloaded 270 miRNA-disease pairs from the literature,²⁷ removed 19 miRNAs that could not be found in the literature,²⁷ and kept 99 miRNAs and 51 diseases including 242 disease-miRNA pairs, which we refer to as the gold standard dataset.

To verify that our method has better universality, we downloaded another disease-miRNA association data set from the literature,²⁷ which contains 1616 experimentally verified human miRNA-disease associations. After merging different miRNA records and unifying the names of miRNA and disease, the data set eventually retained 1395 disease-miRNA associations, including 271 miRNA and 137 diseases. We refer to the data set as predictive dataset.

miRNA-miRNA functional similarity score is downloaded from the literature.²⁷ The data set is successfully applied to multiple methods.^{80,93-95} We use matrix SM to represent the adjacency matrix of miRNA, and $SM(i, j)$ is the score of functional similarity score between miRNA i and miRNA j .

Disease similarity data are downloaded from the literature.⁹⁶ We use matrix SD to represent the adjacency matrix of disease, $SD(i, j)$ representing the similarity score between d_i and disease d_j . The family information of miRNA is obtained from miRBase database.⁹⁷ The family information of miRNA is represented by matrix SM^{fam} . If two miRNAs are in the same family, the corresponding set $SM^{fam}(i, j)$ is 1, otherwise it will set 0.

Algorithm flow

The basic work flow of disease-related miRNA prediction method based on network consistency has four steps (Fig. 1). Namely:

(1) **Building a global similarity network.** The global similarity network of disease is constructed by using the known disease and miRNA association information, the semantic score between the diseases and the Laplacian score of graphs. The global similarity network of the miRNA is constructed by utilizing the miRNA family information, the miRNA function similarity and the Laplacian score of graphs.

(2) **Reconstruction of disease-miRNA association network.** The disease and the miRNA association information and the global similarity between the miRNA nodes are utilized to construct the disease-miRNA association network ASm based on the global similarity information of the miRNA. The disease and miRNA association information and the global similarity between the disease nodes are used to construct the disease-miRNA association network ASD based on the global similarity information of the disease.

(3) **Information diffusion based on network consistency.** The miRNA consistency network diffusion seed is obtained by using the disease global similarity network and the disease-miRNA association network ASm based on the miRNA global similarity information. Then the stable diffusion spectrum is obtained by random walk in the global similarity network of the disease, which is used as the score of miRNA-disease association prediction based on miRNA network consistency information diffusion; the disease consistency network diffusion seed is obtained by using the miRNA global similarity network and the disease-miRNA association network ASD based on the disease global similarity information, then the stable diffusion spectrum is obtained by random walk in the global similarity network of miRNA as the disease-miRNA association prediction algorithm based on the disease network consistency information diffusion.

(4) **Information fusion.** The final score of miRNA-disease association prediction is calculated by the weighted calculation of the two predicted scores in the previous paragraph. The higher the score, the greater the probability that there is a correlation between the miRNA nodes m_i and the disease nodes d_j .

Step 1: similarity network construction

We integrate the known information of disease-miRNA association and the similarity of the disease semantic to obtain the similarity network of the disease. Then we use the Laplacian score of graphs to find the similarity of the disease to express the similarity between the diseases. We use the miRNA family information and the miRNA function similarity data to construct the miRNA similarity network. Laplacian score of graphs is used to find the global similarity of miRNA to represent the similarity between miRNA.

(1) **The construction of disease global similarity network.** The disease global similarity network is constructed in three steps. First, the disease similarity score in the known associated






Fig. 1 The flow chart of information diffusion method based on network consistency is divided into four steps: (1) building a global similarity network. (2) Reconstruction of disease-miRNA association network. (3) Information diffusion based on network consistency. (4) Information fusion.

network structure is obtained through the association between the known disease and miRNA. Then this score and the semantic score between diseases are weighted. Thereafter, the global similarity network of disease is obtained by the Laplace score of the weighted network.

Based on the hypothesis that the phenotype resemblance of disease tendency is associated with function related miRNA,²⁷ we believe that the more common miRNA of two diseases are, the more similar the two diseases are. When the two diseases share the same amount of miRNA, if the miRNA of these two diseases is less, the two diseases are more similar. When there is no common miRNA between disease d_i and disease d_j , the score of known association network structure is set to 0 directly. The formula is as follows:

$$SDAS(i, j) = \begin{cases} \frac{\text{comm}(d_i, d_j)}{\deg(d_i) + \deg(d_j)} & \text{comm}(d_i, d_j) \neq 0 \\ 0 & \text{comm}(d_i, d_j) = 0 \end{cases} \quad (1)$$

SDAS(i, j) indicates the similarity score between disease d_i and disease d_j . comm(d_i, d_j) indicates the number of miRNA shared by disease d_i and disease d_j . $\deg(d_i)$ and $\deg(d_j)$ were respectively the degrees of disease d_i and disease d_j in disease-miRNA bipartite network (that is, the number of miRNA associated with disease d_i and disease d_j).

Then we integrate the semantic correlation information of the disease and the score of the known association network structure to get the weighted score.

$$SDD(i, j) = \frac{SDAS(i, j) + SD(i, j)}{2} \quad (2)$$

SDAS(i, j) indicates the score of the known correlation network structure between disease d_i and disease d_j . SD(i, j) is the semantic similarity score between disease d_i and disease d_j .

Then we seek global similarity. Binary vector $d = \{d_1, d_2, \dots, d_n\}$ is used to represent the initial vector of disease d_i . The corresponding d_i values were set to 1 and the rest were 0. The global similarity between diseases is obtained by Laplacian score of graphs \tilde{d} . It can be solved by the optimization problem of formula (3).⁹⁸

$$\min_{\alpha} \sum_{i,j} \overline{\text{SDD}}_{i,j} (\tilde{d}_i - \tilde{d}_j)^2 + \frac{1-\alpha}{\alpha} \sum_i (\tilde{d}_i - \tilde{d}_j)^2 \quad (3)$$

In formula (3), the previous one is a smooth penalty item, $\overline{\text{SDD}}$ is the normalized matrix of the matrix SDD, which guarantees similar score for similar diseases. The second penalty items obtained the consistency between the disease and other diseases. α is a balance factor with a range of $\alpha \in (0,1)$. This factor is used to balance two penalty items' weight in formula (3). The approximate solution of formula (3) is as follows⁹⁸:

$$\tilde{d} = (1-\alpha)(I - \alpha\overline{\text{SDD}})^{-1}d \quad (4)$$

With the above method, we can get the global similarity score of all diseases in the disease network, which is represented by matrix SMLAPLACIAN.

(2) Construction of miRNA global similarity network. Construction of miRNA global similarity network is divided into two steps. First, miRNA similarity network is constructed by using miRNA similarity score and miRNA family information calculated by Wang *et al.*²⁷ Then we use the Laplacian score of miRNA similarity network to get the global similarity score of miRNA.

Bandyopadhyay *et al.*²⁶ found that the more the shared mRNA target targets were in the same family miRNA, the more similar their functions were. In order to make full use of family information of miRNA, we give higher weight to miRNA belonging to the same family when constructing miRNA network.

We use the following formula to calculate the similarity score of miRNA:

$$\text{SIM}(i, j) = \frac{\text{SM}(i, j) + \text{SM}^{\text{fam}}(i, j)}{2} \quad (5)$$

Among them, $\text{SIM}(i, j)$ represents the similarity score between miRNA node m_i and miRNA node m_j after merging two kinds of information. $\text{SIM}(i, j)$ is a functional similarity score between miRNA m_i and miRNA m_j calculated by Wang *et al.*²⁷ SM^{fam} is the miRNA family information matrix. When miRNA m_i and miRNA m_j are in the same family, $\text{SM}^{\text{fam}}(i, j)$ equals 1, which gives a higher score between two miRNA.

Then the global similarity weight matrix of miRNA is obtained by finding Laplacian score of graphs:

$$\text{SMLAPLACIAN} = (1-\beta)(I - \beta\overline{\text{SIM}})^{-1} \quad (6)$$

SMLAPLACIAN represents miRNA global similarity network score matrix. I is a n_m dimensional unit matrix, and n_m is the total number of miRNA. $\overline{\text{SIM}}$ is the normalization matrix of miRNA similarity score SIM. β is a balance factor and $\beta \in (0, 1)$.

Step2: the reconstruction of disease–miRNA association network

From the previous analysis, we know that the known experimentally validated disease–miRNA association network is a Boolean bipartite network, which cannot fully characterize the tightness of the disease–miRNA association. We restructured the disease–miRNA association network by using the global similarity of the disease and the global similarity of the miRNA. Respectively, they are accounted as the disease–miRNA correlation network ASm based on the global similarity information of miRNA and the disease–miRNA correlation network ASD based on the global similarity information of the disease.

(1) Construction of disease–miRNA correlation network ASm based on miRNA global similarity information. Here we reconstruct the weight of the disease node d_j and the miRNA node m_i by introducing all the association information of the miRNA nodes m_k and the disease nodes d_j and the global similarity between the miRNA nodes. The calculation formula is as follows:

$$\text{ASm}(j, i) = \text{AS}'(j, i) + \lambda \sum_{k=1}^{n_m} \text{SMLAPLACIAN}(m_i, m_k) \times \text{AS}(k, j) \quad (7)$$

Among them, $\text{ASm}(j, i)$ is the weight of disease node d_j to miRNA node m_i in disease–miRNA bipartite network after reconstruction. $\text{AS}(i, j)$ is the weight of miRNA nodes m_i and disease nodes d_j in the bipartite network before reconstruction. (In the experimentally verified disease–miRNA Boolean bipartite network, if the miRNA node m_i is known to be associated with the disease node d_j , the value is 1. Otherwise the value is 0.) AS' is the transposed matrix of AS. $\text{SMLAPLACIAN}(m_i, m_k)$ is the weight between the miRNA node m_i and the miRNA node m_k in the miRNA global similarity network. n_m is the total number of miRNA, and λ is a balance parameter.

(2) Construction of disease–miRNA correlation network ASD based on disease global similarity information. We reconstruct the miRNA node m_i and the weight of the disease node d_j by introducing the association information of all the disease nodes d_k and the miRNA node m_i and the global similarity between the disease nodes. The calculation formula is as follows:

$$\text{ASD}(i, j) = \text{AS}(i, j) + \eta \sum_{k=1}^{n_d} \text{AS}(i, k) \times \text{SMLAPLACIAN}(d_k, d_j) \quad (8)$$

Among them, $\text{ASD}(i, j)$ is the weight of miRNA node m_i and disease node d_j in the reconstructed miRNA–disease bipartite network. $\text{AS}(i, j)$ is used to reconstruct the weight of miRNA



nodes m_i and disease nodes d_j in the miRNA–disease bipartite network before reconstruction. $\text{SDLAPLACIAN}(d_k, d_j)$ is the weight of disease nodes d_k and disease nodes d_j in the global similarity network of diseases. n_d is the total number of diseases. η is a balance parameter.

Step3: information diffusion based on network consistency

Based on the hypothesis that functionally similar miRNA is usually associated with phenotypically similar diseases, we designed an information diffusion method based on network consistency to reveal the potential association between miRNA and disease. We use network consistency to describe the relationship between two vectors in the same order and the same object. By using the similarity in the change rule of these two vectors, we can get comprehensive information of two heterogeneous networks. The projection of vectors can be used to express the degree of association between two vectors.

(1) **Information diffusion based on miRNA network consistency(IDMNC).** First, we used the adjacency matrix of the disease global similarity network and the disease–miRNA association network ASm based on the miRNA global similarity information to do matrix multiplication, and got the miRNA consistency network diffusion seed. In the global similarity network, $\text{SDLAPLACIAN}(j, :)$ represents the global similarity between disease d_j and other disease nodes. $\text{ASm}(:, i)$ represents the correlation between miRNA nodes m_i and all other disease nodes. At this point, we use network consistency to describe $\text{SDLAPLACIAN}(j, :)$ and $\text{ASm}(:, i)$ as related disease nodes in the same order with the data relation of two different objects, the disease d_j and the miRNA node m_i , which are similar to the two vectors. The projection of $\text{SDLAPLACIAN}(j, :)$ on $\text{ASm}(:, i)$ represents the degree of association of the miRNA node m_i with the disease node d_j after integrating the information of the two heterogeneous networks, the miRNA–disease information association network and the disease global similarity network. Correlation degree of all miRNA nodes and disease nodes is calculated as follows:

$$\text{SEEDM} = \text{SDLAPLACIAN} \times \text{ASm} \quad (9)$$

Next, in order to accurately describe the degree of association between miRNA nodes and disease nodes, we used random walk algorithm to walk in the global similarity network of disease, and captured the stable distribution of information called stable spread spectrum. Then the data of stable diffusion spectrum are utilized to represent the correlation between miRNA nodes and disease nodes. After the matrix normalization, each column is the seed sequence of associations between the miRNA node m_i and all the disease nodes. The stable diffusion spectrum is obtained by SDLAPLACIAN random diffusion of these seed sequences in the adjacency matrix of the disease consistency network.

$$\text{MTD}_{t+1}(i) = (1 - \gamma) \times \overline{\text{SDLAPLACIAN}} \times \text{MTD}_t(i) + \gamma \times \overline{\text{SEEDM}}(:, i) \quad (10)$$

$\overline{\text{SEEDM}}(:, i)$ is the information of column i after the normalization of SEEDM matrix. The column vector is the seed sequence of the associations between miRNA node m_i and all disease nodes. $\overline{\text{SDLAPLACIAN}}$ is the normalized matrix of the adjacency matrix SDLAPLACIAN of the disease consistency network. γ is the restart probability. $\text{MTD}_t(i)$ vector represents the information distribution after t iterations. After several iterations, the probability space can reach the steady state $\text{MTD}_\infty(i)$ ($|\text{MTD}_{t+1}(i) - \text{MTD}_t(i)| < 10^{-6}$) and stop the iteration. When the state is stable, the value of the vector is the correlation score between miRNA node m_i and each disease. The correlation scores of all miRNA nodes and disease nodes are expressed by matrix MTD .

(2) **Information diffusion based on disease network consistency(IDDNC).** Similar to the above, in the miRNA global similarity network, $\text{SMLAPLACIAN}(i, :)$ represents the global similarity between the miRNA node m_i and the remaining miRNA nodes. $\text{ASd}(:, j)$ represents the correlation between disease nodes d_j and all other miRNA nodes. At this point, we use network consistency to describe $\text{SMLAPLACIAN}(i, :)$ and $\text{ASd}(:, j)$ as related miRNA nodes in the same order with the data relation between two objects, the miRNA node m_i and the disease node d_j , which are similar to the two vectors. The projection of $\text{SMLAPLACIAN}(i, :)$ on $\text{ASd}(:, j)$ represents the degree of association of the miRNA node m_i with the disease node d_j after integrating the information of the two heterogeneous networks. We used the miRNA global similarity network adjacency matrix and the disease–miRNA association network ASd based on the disease global similarity information to do matrix multiplication, and got the disease consistency network diffusion seed. The formula is as follows:

$$\text{SEEDD} = \text{SMLAPLACIAN} \times \text{ASd} \quad (11)$$

The seed matrix of the disease node d_j is obtained through the above formula. After normalization of the matrix, each column is used as the seed sequence of the disease node d_j and all miRNA. These seed sequences are SMLAPLACIAN randomly spread in the adjacency matrix of the miRNA consistency network in order to obtain stable diffusion spectra:

$$\text{DTM}_{t+1}(j) = (1 - \theta) \times \overline{\text{SMLAPLACIAN}} \times \text{DTM}_t(j) + \theta \times \overline{\text{SEEDD}}(:, i) \quad (12)$$

$\overline{\text{SMLAPLACIAN}}$ is the normalized matrix of the adjacency matrix SMLAPLACIAN of the miRNA consistency network. θ is the restart probability. $\text{DTM}_t(j)$ vector represents information distribution after t iterations. After several iterations, the probability space can reach a stable state $\text{DTM}_\infty(j)$ ($|\text{DTM}_{t+1}(j) - \text{DTM}_t(j)| < 10^{-6}$), and then the iteration can be stopped. Each value of the vector represents the correlation score of disease j and each miRNA. The correlation score of all diseases and each miRNA is expressed by matrix DTM .

Step4: information fusion

Finally, we integrated the two prediction scores obtained in the third step to form the final prediction score.



$$MD(i, j) = w \times MTD'(i, j) + (1 - w) \times DTM(i, j) \quad (13)$$

$MD(i, j)$ is the final prediction score of miRNA node m_i and disease node d_j . The greater the score, the greater the probability that miRNA node m_i is associated with disease node d_j .

Results

Parameter selection

The proposed method has four kinds of parameters: the information diffusion restart parameters γ and θ ; the equilibrium factor α constructing the disease global similarity network, the equilibrium factor β constructing the miRNA global similarity network; equilibrium parameter λ based on global similarity network information for reconstructing the disease–miRNA association network ASm of miRNA, equilibrium parameter η based on disease global similarity network information for reconstructing the miRNA–disease association network ASD; the weight parameter w of information diffusion disease-related miRNA prediction score based on network consistency.

The selection and influence of these four kinds of parameters are discussed respectively. In the process of information diffusion, γ and θ indicate the probability of repetitive random walks that represent random callbacks to the source node. The greater γ and θ are, the greater the probability of returning the node for each step is. For the sake of simplicity, we set γ and θ to the same size. To verify the impact of γ and θ on the performance of the prediction algorithm, the other parameters are fixed ($\alpha = \beta = \lambda = \eta = w = 0.5$) while the values of γ and θ are changed (0.1 for step length, from 0.1 to 0.9) to do cross-validation on the gold benchmark dataset and to calculate the AUC value. The experimental results are shown in Fig. 2. In the experiment, we found that when γ and θ increased from 0.1 to 0.9, the AUC value increased gradually from 0.7656 to 0.8460. The best prediction performance was obtained when the maximum value was obtained at 0.9.

Then we set the balance factor α of the disease global similarity network and the balance factor β of the miRNA consistency network as the same. To verify the impact of such parameters on the predictive performance of the algorithm, other parameters are fixed on the basis of the previously

obtained parameters ($\gamma = \theta = 0.9$, $\lambda = \eta = w = 0.5$), and then the α and β values are changed (with 0.1 for step length, from 0.1 to 0.9). As you can see from Fig. 2 with the increase of α and β , the AUC value gradually decreases. When $\alpha = \beta = 0.1$, the AUC value is the largest and the prediction performance is the best.

In order to measure the degree of disease–miRNA association more accurately, we used the global similarity of the disease and the global similarity of miRNA to reconstruct the disease–miRNA association network respectively. The balance parameters λ and η determine the contribution rate of other diseases and other miRNA to the disease–miRNA association network. To verify the impact of the two parameters on the predictive performance of the algorithm, other parameters are fixed on the basis of the previously obtained parameters ($\gamma = \theta = 0.9$, $\alpha = \beta = 0.1$, $w = 0.5$), and then the λ and η values are changed (from 0 to 0.9) for cross-validation. In the experiment, it was found that the AUC value was 0.8670 when the set value is 0.1 (0.8748 when the set value is 0.2; 0.8745 when the set value is 0.3; 0.8743 when the set value is 0.4). At this time, the AUC value was not very different. When the set value changes from 0.4, AUC decreased slowly. With the increase of λ and η , the AUC value became smaller and decreased to 0.8618 when the set value is 0.9.

In order to obtain the best prediction performance, we got the final correlation prediction score of the miRNA–disease association by weighting the miRNA–disease association prediction algorithm score (based on miRNA network consistency information diffusion) and the disease–miRNA association prediction algorithm score (based on disease network consistency information diffusion). The score weight parameter of miRNA–disease correlation prediction based on miRNA network consistency information diffusion is set as w ($0 \leq w \leq 1$), then $1 - w$ is the weight of disease–miRNA association prediction score based on disease network consistency information diffusion. When the w is larger, the weight of the miRNA–disease correlation prediction score based on miRNA network consistency information diffusion is greater, which means that the prediction results take more consideration of the miRNA–disease correlation prediction score based on miRNA network consistency information diffusion. When the w is smaller, the prediction results take more consideration of the disease–miRNA association prediction score based on disease network consistency information diffusion. Based on the previous discussion, we fixed the values of other parameters ($\gamma = \theta = 0.9$, $\alpha = \beta = 0.1$, $\lambda = \eta = 0.3$), and then changed the value of w (from 0 to 0.9). When w increases from 0.1 to 0.7, the AUC value increases gradually. When the w increases from 0.7 to 0.9, the AUC value gradually decreases. When w is 0.7, the prediction effect is the best, and AUC achieves the maximum value of 0.8814. When λ and η are set as 0.2 and 0.4, the experiment result is similar, that is, when w is 0.7, the prediction effect is the best.

Finally, we determine that the parameters are: $\gamma = \theta = 0.9$, $\alpha = \beta = 0.1$, $\lambda = \eta = 0.3$, $w = 0.7$.

Performance evaluation

In this paper, a disease-related miRNA prediction model based on network consistency information diffusion is proposed,




Fig. 2 Influence of parameter variation on model prediction accuracy.



which is the integration of the miRNA–disease correlation prediction score (based on miRNA network consistency information diffusion) and the disease–miRNA correlation prediction score (based on disease network consistency information diffusion). In the construction of the similarity network, we restructured the disease and miRNA in different ways, and used the global similarity score as the similarity score to measure the relationship between the nodes. When we tested the model, we considered the following nine cases falling into three categories: (1) information diffusion method based on miRNA network consistency without considering the miRNA network reconstruction (IDMNC without MNR); (2) information diffusion method based on disease network consistency without considering the disease network reconstruction (IDDNC without DNR); (3) information diffusion method based on network consistency without considering the network reconstruction (IDNC without NR); (4) information diffusion method based on miRNA network consistency by considering the miRNA network reconstruction with family information (IDMNC with FR); (5) information diffusion method based on disease network consistency by considering the miRNA network reconstruction with family information (IDDNC with FR); (6) information diffusion method based on network consistency by considering the miRNA network reconstruction with family information (IDNC with FR); (7) information diffusion method based on miRNA network consistency by considering the network reconstruction (IDMNC); (8) information diffusion method based on disease network consistency by considering the network reconstruction (IDDNC); (9) information diffusion method based on network consistency by considering the network reconstruction (IDNC). Based on the above conditions, parameters are selected on the gold standard dataset: $\gamma = \theta = 0.9$, $\alpha = \beta = 0.1$, $\lambda = \eta = 0.3$, $w = 0.7$. The calculated ROC curve and the AUC value are shown in Fig. 3.

From Fig. 3, Information diffusion based on miRNA network consistency method, information diffusion based on disease network consistency method and information diffusion method based on network consistency method are gradually improved in the prediction accuracy.

The prediction accuracies of non network reconstruction, reconstruction of miRNA network with family information, reconstruction of both disease and miRNA network are gradually improved. When using all the information, the AUC value is 0.8814. When the method is information diffusion based on miRNA network consistency without network reconstruction, AUC value is only 0.7171. This fully demonstrated the effectiveness of our method of restructuring network and the feasibility of integrating the two scoring methods with the weighted method.

Comparison with other methods

We compared the algorithm proposed in this paper with three classical methods RLSMDA,³⁷ NetCBI,⁹⁹ GSTRW. In the LOOCV assessment, each known miRNA–disease association is considered as a test sample, while other known associations are considered as training samples. The miRNA–disease




Fig. 3 The ROC curve and AUC value for LOOCV in three classes of nine cases.

association without known evidence is considered to be a candidate sample. In the gold datum data set, the AUC value of NetCBI is 0.8001; the AUC value of RLSMDA is 0.8059; the AUC value of GSTRW is 0.8479; and the AUC value of the algorithm proposed in this paper is 0.8814, which is far superior to the other three methods. The ROC curves and AUC values of the four methods on the gold datum data set are shown in Fig. 4.

In order to avoid data dependence, we further verified the four methods on the forecast data set, and the AUC values of the four methods in the forecast dataset have been greatly improved. As shown in Fig. 5, the AUC value of NetCBI is 0.9053; the AUC value of RLSMDA is 0.9232; the AUC value of GSTRW is 0.9434; and the AUC value of the algorithm proposed in this paper is 0.9512. This is mainly due to the increase in the number of available disease–miRNA associations, and the higher accuracy of the constructed similarity network, which makes the prediction accuracy increase. Both in the gold datum data set, or in the forecast data set, the methods presented in this paper have shown strong predictive ability, especially in the case of less number of disease–miRNA associations. Because the method proposed in this paper takes advantage of global similarity and network consistency, the algorithm proposed in this paper has more advantages.




Fig. 4 The ROC curve and AUC value of our method compared with other methods on the gold benchmark dataset.






Fig. 5 The ROC curve and AUC value of our method compared with other methods in the predictive dataset.

The prediction of new miRNA and isolated disease

The new miRNA refers to the unknown miRNA associated with the disease. With the discovery of a large number of unknown miRNA, the new miRNA prediction becomes more important in the prediction of disease–miRNA association. This paper also used the LOOCV to predict the new miRNA. One by one, we removed the association information of verified miRNA with all other diseases and simulated them as new miRNA. In the gold benchmark dataset, the AUC value of our method is 0.8087. Its ROC curve and the AUC value are shown in Fig. 6, which is higher than the AUC value predicted by RLSMDA and NetCBI for the common disease. This shows that our method has a better prediction ability for the new miRNA.

Isolated diseases refer to diseases whose associations with miRNA are unknown. Prediction of isolated diseases is also a difficult problem to be solved in the prediction of disease–miRNA associations. Similarly, in order to test the predictive performance of this article on isolated diseases, we removed the associations between disease and miRNA. The ROC curve and AUC value obtained with LOOCV are listed in Fig. 6. It can be seen from the figure that the AUC predicted by this algorithm for isolated diseases is 0.7562. This shows that our method has certain predictive ability for isolated diseases, but the accuracy of prediction needs to be further improved.




Fig. 6 Results of our prediction method of new miRNA and isolated diseases in gold datum dataset.

Case studies

In 2017, 135 430 new cases of colon neoplasms were reported in the United States. Among them, 50 260 cases of colon neoplasms led to death.¹⁰⁰ Colon neoplasms is associated with many miRNA, such as miR-126, which inhibits the growth of colon tumor cells;¹⁶ miR-21 has a high expression level in colon neoplasms cells.¹⁸ Using the calculation method to predict the association between colon neoplasms and miRNA can help us to diagnose the cancer patients in the early stage. This is of great importance to increase the survival rate of colon neoplasms patients. Therefore, it is urgent to develop a scientific method to forecast the miRNA which is related to colon neoplasms disease. In the forecast dataset, 37 miRNA related to colon tumors were experimentally verified. We used the method proposed in this article to experiment with colon tumors by using these 37 known associations and considering both disease similarity and miRNA similarity. Among the first 50 unknown disease–miRNA associations got in the experiment, 45 miRNA got supporting evidence in the updated HMDD, miR2Disease, and dbDEMC data sets (shown in Table 1). Only 5 miRNA have not been verified, which are hsa-mir-199a, hsa-mir-92b, hsa-mir-200a, hsa-mir-373 and hsa-mir-216b. However, in previous literatures, we have found supporting evidence, for example: Nonaka *et al.*¹⁰¹ found that miR-199a could be used as a biomarker for colorectal cancer; Mussnich *et al.*¹⁰² found that miR-199a and miR-375 affect the sensitivity of colon neoplasms cells to cetuximab by targeting PHLPP1. Niu *et al.*¹⁰³ stated that hsa-miR-92b can be used as a reference gene for circulating microRNA in colorectal cancer. Pichler *et al.*¹⁰⁴ found that miR-200a regulates the prognosis of patients with rectal cancer by regulating the expression of epithelial mesenchymal metastasis related genes. Tanaka *et al.*¹⁰⁵ found that the apparent silencing of microRNA-373 played an important regulatory role in the proliferation of colon neoplasms cells. Previous studies also suggested that these miRNA are closely related to colon neoplasms, such as hsa-mir-199a and hsa-mir-200a, which are predicted to be associated with colon tumors in PBMDA,⁸⁵ MCMDA,⁵⁴ EGBMMDA.⁴⁸ The two miRNA, hsa-mir-92b and hsa-mir-200a, were predicted to be associated with colon neoplasms in the case analysis of RLSMDA. These documents are published after the latest update date of the three databases, which fully demonstrates the strong predictive power of our method.

Breast neoplasms is one of the most important causes of cancer death in women every year. So many scientists have been studying the pathology of breast neoplasms. The study of the relationship between microRNA and breast neoplasms can help us understand the development of the disease at a molecular point of view. Of the first 50 unknown associations for breast neoplasms, only 3 were not verified: hsa-mir-518b, hsa-mir-612 and hsa-mir-657, which are shown in Table 2. hsa-miR-21 is significantly associated with many diseases, which can be proved by breast neoplasms related evidences in HMDD, miR2Disease and dbDEMC. Persson *et al.*¹⁰⁶ stated that hsa-miR-4656 is associated with breast neoplasms. hsa-miR-21, hsa-miR-612 and hsa-miR-4656 share many common target genes.¹⁰⁷ This indicates that these miRNA may have similar



Table 1 Prediction of the top 50 predicted miRNAs associated with colon neoplasms based on known associations in HMDD database

Rank	miRNA name	Evidences	Rank	miRNA name	Evidences
1	hsa-mir-196a	dbDEMC, miR2Disease	26	hsa-mir-421	dbDEMC
2	hsa-mir-199a	Unconfirmed	27	hsa-mir-15b	dbDEMC, miR2Disease
3	hsa-mir-448	dbDEMC	28	hsa-mir-30d	dbDEMC
4	hsa-mir-25	dbDEMC	29	hsa-mir-29a	HMDD, dbDEMC, miR2Disease
5	hsa-mir-122	dbDEMC	30	hsa-mir-451	dbDEMC, miR2Disease
6	hsa-mir-181b	dbDEMC, miR2Disease	31	hsa-mir-203	dbDEMC
7	hsa-mir-18b	dbDEMC	32	hsa-mir-212	dbDEMC
8	hsa-mir-224	dbDEMC	33	hsa-mir-30b	dbDEMC
9	hsa-mir-15a	HMDD, dbDEMC	34	hsa-mir-106b	HMDD, miR2Disease, dbDEMC
10	hsa-mir-92b	Unconfirmed	35	hsa-mir-214	dbDEMC
11	hsa-mir-372	dbDEMC, miR2Disease	36	hsa-mir-98	dbDEMC
12	hsa-mir-34c	dbDEMC	37	hsa-mir-220	dbDEMC
13	hsa-mir-200a	Unconfirmed	38	hsa-mir-137	HMDD, dbDEMC, miR2Disease
14	hsa-mir-190	dbDEMC	39	hsa-mir-33a	dbDEMC
15	hsa-mir-217	dbDEMC	40	hsa-mir-216b	Unconfirmed
16	hsa-mir-222	dbDEMC	41	hsa-mir-33b	dbDEMC
17	hsa-mir-205	HMDD, dbDEMC	42	hsa-mir-216a	dbDEMC
18	hsa-mir-93	dbDEMC	43	hsa-mir-199b	dbDEMC
19	hsa-mir-20b	dbDEMC	44	hsa-mir-429	dbDEMC
20	hsa-mir-135b	HMDD, miR2Disease, dbDEMC	45	hsa-mir-376c	dbDEMC
21	hsa-mir-34b	dbDEMC	46	hsa-mir-16	HMDD, dbDEMC
22	hsa-mir-29c	dbDEMC	47	hsa-mir-146b	dbDEMC
23	hsa-mir-373	Unconfirmed	48	hsa-mir-302b	HMDD, dbDEMC
24	hsa-mir-125b	dbDEMC	49	hsa-mir-125a	dbDEMC, miR2Disease
25	hsa-mir-9	dbDEMC	50	hsa-mir-95	dbDEMC

biological processes. So we highly believe that hsa-miR-612 is associated with breast neoplasms. In addition, we found that the three miRNA appeared in the breast neoplasms related miRNA collection in SDMMDA.⁹¹ Among them, hsa-mir-518b is located in the fifth position while hsa-mir-612 and hsa-mir-657 are located in the 22nd and 23rd positions respectively.

The prediction of isolated disease and new miRNA

In order to verify our algorithm's ability to predict isolated diseases, we removed the known associations of miRNAs with the proven diseases, which ensures that we only use the similarity information of the confirmed disease and other diseases

Table 2 Prediction of the top 50 predicted miRNAs associated with breast neoplasms based on known associations in HMDD database

Rank	miRNA name	Evidences	Rank	miRNA name	Evidences
1	hsa-mir-518b	Unconfirmed	26	hsa-mir-658	dbDEMC
2	hsa-mir-518c	dbDEMC	27	hsa-mir-575	dbDEMC
3	hsa-mir-612	Unconfirmed	28	hsa-mir-423	HMDD, dbDEMC
4	hsa-mir-600	dbDEMC	29	hsa-mir-500	dbDEMC
5	hsa-mir-629	HMDD, dbDEMC	30	hsa-mir-346	HMDD, dbDEMC
6	hsa-mir-622	dbDEMC	31	hsa-mir-99a	dbDEMC
7	hsa-mir-638	HMDD, dbDEMC	32	hsa-mir-130b	dbDEMC
8	hsa-mir-486	HMDD, dbDEMC	33	hsa-mir-208b	dbDEMC
9	hsa-mir-596	dbDEMC	34	hsa-mir-134	dbDEMC
10	hsa-mir-557	dbDEMC	35	hsa-mir-433	dbDEMC
11	hsa-mir-642	dbDEMC	36	hsa-mir-484	dbDEMC
12	hsa-mir-769	dbDEMC	37	hsa-mir-663	dbDEMC
13	hsa-mir-602	dbDEMC	38	hsa-mir-365	HMDD, dbDEMC
14	hsa-mir-611	dbDEMC	39	hsa-let-7e	HMDD, dbDEMC
15	hsa-mir-185	dbDEMC	40	hsa-mir-494	dbDEMC
16	hsa-mir-583	dbDEMC	41	hsa-let-7i	HMDD, miR2Disease, dbDEMC
17	hsa-mir-615	dbDEMC	42	hsa-let-7b	HMDD, dbDEMC
18	hsa-mir-654	dbDEMC	43	hsa-mir-198	dbDEMC
19	hsa-mir-662	dbDEMC	44	hsa-mir-373	HMDD, miR2Disease, dbDEMC
20	hsa-mir-601	dbDEMC	45	hsa-mir-203	HMDD, miR2Disease, dbDEMC
21	hsa-mir-324	HMDD, dbDEMC	46	hsa-mir-223	HMDD, dbDEMC
22	hsa-mir-608	HMDD	47	hsa-let-7g	HMDD, dbDEMC
23	hsa-mir-637	dbDEMC	48	hsa-mir-101	HMDD, dbDEMC
24	hsa-mir-657	Unconfirmed	49	hsa-mir-92b	dbDEMC
25	hsa-mir-197	HMDD, dbDEMC	50	hsa-let-7c	HMDD, dbDEMC



Table 3 The top 50 colon neoplasms-related miRNAs candidates predicted by IDNC with removed all known colon neoplasms–miRNAs associations and the confirmation of these associations

Rank	miRNA name	Evidences	Rank	miRNA name	Evidences
1	hsa-mir-21	HMDD, miR2Disease, dbDEMC	26	hsa-mir-19b	HMDD, miR2Disease, dbDEMC
2	hsa-mir-15a	HMDD, dbDEMC	27	hsa-mir-92a	HMDD, dbDEMC
3	hsa-mir-451	dbDEMC, miR2Disease	28	hsa-let-7a	HMDD, miR2Disease, dbDEMC
4	hsa-mir-373	Unconfirmed	29	hsa-mir-10a	dbDEMC, miR2Disease
5	hsa-mir-16	HMDD, dbDEMC	30	hsa-mir-205	HMDD, dbDEMC
6	hsa-mir-155	HMDD, miR2Disease, dbDEMC	31	hsa-mir-211	Unconfirmed
7	hsa-mir-29c	dbDEMC	32	hsa-mir-200b	HMDD, dbDEMC
8	hsa-mir-34a	HMDD, miR2Disease, dbDEMC	33	hsa-mir-196a	dbDEMC, miR2Disease
9	hsa-mir-19a	HMDD, miR2Disease, dbDEMC	34	hsa-mir-181a	dbDEMC, miR2Disease
10	hsa-mir-17	HMDD, dbDEMC	35	hsa-mir-141	HMDD, miR2Disease, dbDEMC
11	hsa-mir-221	HMDD, miR2Disease, dbDEMC	36	hsa-let-7e	HMDD, dbDEMC
12	hsa-mir-125b	dbDEMC	37	hsa-mir-145	HMDD, miR2Disease, dbDEMC
13	hsa-mir-302b	HMDD, dbDEMC	38	hsa-mir-223	HMDD, miR2Disease, dbDEMC
14	hsa-mir-372	dbDEMC, miR2Disease	39	hsa-let-7d	HMDD, dbDEMC
15	hsa-mir-143	HMDD, miR2Disease, dbDEMC	40	hsa-let-7b	HMDD, miR2Disease, dbDEMC
16	hsa-mir-20a	HMDD, miR2Disease, dbDEMC	41	hsa-mir-9	dbDEMC
17	hsa-mir-184	dbDEMC	42	hsa-let-7c	HMDD, dbDEMC
18	hsa-mir-181b	dbDEMC, miR2Disease	43	hsa-let-7i	HMDD, dbDEMC
19	hsa-mir-29a	HMDD, dbDEMC, miR2Disease	44	hsa-let-7f	HMDD, dbDEMC
20	hsa-mir-122	dbDEMC	45	hsa-let-7g	HMDD, miR2Disease, dbDEMC
21	hsa-mir-18a	HMDD, miR2Disease, dbDEMC	46	hsa-mir-15b	dbDEMC, miR2Disease
22	hsa-mir-146a	HMDD, dbDEMC	47	hsa-mir-92b	Unconfirmed
23	hsa-mir-222	dbDEMC	48	hsa-mir-30a	HMDD, dbDEMC
24	hsa-mir-212	dbDEMC	49	hsa-mir-126	HMDD, dbDEMC
25	hsa-mir-137	HMDD, dbDEMC, miR2Disease	50	hsa-mir-19b	HMDD, miR2Disease, dbDEMC

and the miRNAs information associated with other diseases. We used colon neoplasms and breast neoplasms as case studies. The results are shown in Tables 3 and 4 respectively.

For colon neoplasms, 37 known associations of miRNAs with colon neoplasms were removed. Among the first 50 miRNAs predicted, 47 miRNAs were identified in the three databases while three miRNAs, hsa-mir-373, hsa-mir-211 and hsa-mir-92b, failed to find support in the three databases, which is shown in Table 3. However, Cai *et al.*¹⁰⁸ found that hsa-miR-211 promoted the growth of colorectal cancer cells through targeting CHD5. The other two miRNAs were predicted in previous cases about colon tumor. As mentioned above, a number of references to the association of these miRNAs and colonic tumors are also introduced. Therefore, we think our algorithm performs well for the prediction of isolated diseases.

For breast neoplasms, we deleted 78 known associations of breast neoplasms with miRNAs. We used this method to predict a potential association between miRNAs and breast neoplasms. In the first 50 miRNAs projections, 49 were found in the HMDD, miR2Disease, and dbDEMC databases, and only hsa-mir-184 had not been found in the three databases. However, when Yang *et al.*¹⁰⁹ studied the classification of breast tumor subtypes by immunohistochemical markers, it was found that there were differences in expression of hsa-miR-365, hsa-miR-1238 and hsa-miR-184.

Next, we studied the new miRNA association prediction. hsa-mir-21 plays a crucial role in carcinogenesis and can be used as a biomarker for detecting various cancers. In this section, we removed all the associations of hsa-mir-21 with diseases in the

forecast data set. Among the first 50 projected diseases related to hsa-mir-21, 40 diseases are verified in the above three databases while 10 kinds of diseases that are not verified, which is shown in Table 5. But previous literature show that these diseases are associated with hsa-mir-21. For example, Han *et al.*¹¹⁰ discovered that hsa-mir-21 can slow down the apoptosis of cortical neurons by promoting PTEN-Akt signaling pathway *in vitro* after traumatic brain injury. Montalban *et al.*¹¹¹ found that hsa-mir-21 could regulate the growth factor signal and regulate the degeneration of neurons in PC12 cells. Smigelska *et al.*¹¹² found that hsa-mir-21 plays a role in supporting the survival of T cells in CD4+T cells. Zhang *et al.*¹¹³ found that hsa-mir-21 is associated with the development of liver fibrosis. Ding *et al.*¹¹⁴ found that hsa-miR-21 could be used as a new biomarker for diagnosing HBV related acute liver failure through real-time quantitative PCR technology. Liao *et al.*¹¹⁵ found that 80% of the patients with hepatocellular carcinoma have the background of chronic hepatitis B or type C hepatitis and cirrhosis, and hsa-miR-21 can be used for subdivision of hepatocellular carcinoma and chronic hepatitis. Yao *et al.*¹¹⁶ found that compared with patients with obstructive spermatogenesis, miRNA in spermatocytes, such as hsa-miR-21, was decreased in patients with non obstructive spermatogenesis. Gutsaeva *et al.*¹¹⁷ found that hsa-mir-21 is closely related to new vascularization in ischemic retina. Andrade *et al.*¹¹⁸ found differential expression of 11 kinds of miRNA (such as hsa-miR-424 and hsa-miR-21) in the muscles of the patients with amyotrophic lateral sclerosis (rapidly progressive neurodegenerative disease) by microarray. miR-21 plays a crucial role in



Table 4 The top 50 breast neoplasms-related miRNAs candidates predicted by IDNC with removed all known breast neoplasms-miRNAs associations and the confirmation of these associations

Rank	miRNA name	Evidences	Rank	miRNA name	Evidences
1	hsa-mir-21	HMDD, miR2Disease, dbDEMC	26	hsa-mir-10a	HMDD, miR2Disease, dbDEMC
2	hsa-mir-146a	HMDD, miR2Disease, dbDEMC	27	hsa-mir-211	dbDEMC
3	hsa-mir-125b	HMDD, miR2Disease, dbDEMC	28	hsa-mir-137	HMDD, dbDEMC
4	hsa-mir-373	HMDD, miR2Disease, dbDEMC	29	hsa-mir-141	HMDD, miR2Disease, dbDEMC
5	hsa-mir-155	HMDD, miR2Disease, dbDEMC	30	hsa-mir-223	HMDD, dbDEMC
6	hsa-mir-16	HMDD, dbDEMC	31	hsa-let-7e	HMDD, dbDEMC
7	hsa-mir-451	HMDD, miR2Disease	32	hsa-mir-200b	HMDD, miR2Disease, dbDEMC
8	hsa-mir-29c	HMDD, dbDEMC	33	hsa-mir-146b	HMDD, miR2Disease
9	hsa-mir-34a	HMDD, dbDEMC	34	hsa-let-7b	HMDD, dbDEMC
10	hsa-mir-19a	HMDD, dbDEMC	35	hsa-mir-181a	HMDD, miR2Disease, dbDEMC
11	hsa-mir-17	HMDD, dbDEMC	36	hsa-let-7d	HMDD, miR2Disease, dbDEMC
12	hsa-mir-184	Unconfirmed	37	hsa-let-7c	HMDD, dbDEMC
13	hsa-mir-221	HMDD, miR2Disease	38	hsa-let-7i	HMDD, miR2Disease, dbDEMC
14	hsa-mir-15a	HMDD, dbDEMC	39	hsa-mir-9	HMDD, dbDEMC
15	hsa-mir-302b	HMDD, miR2Disease	40	hsa-let-7f	HMDD, miR2Disease, dbDEMC
16	hsa-mir-20a	HMDD, dbDEMC	41	hsa-let-7g	HMDD, dbDEMC
17	hsa-mir-29a	HMDD, dbDEMC	42	hsa-mir-143	HMDD, miR2Disease, dbDEMC
18	hsa-mir-372	HMDD, dbDEMC	43	hsa-mir-145	HMDD, miR2Disease, dbDEMC
19	hsa-mir-18a	HMDD, dbDEMC	44	hsa-mir-92b	dbDEMC
20	hsa-mir-222	HMDD, dbDEMC	45	hsa-mir-30a	HMDD, dbDEMC
21	hsa-mir-181b	HMDD, miR2Disease, dbDEMC	46	hsa-mir-150	HMDD, dbDEMC
22	hsa-mir-19b	HMDD, dbDEMC	47	hsa-mir-15b	dbDEMC
23	hsa-mir-92a	HMDD, dbDEMC	48	hsa-mir-127	HMDD, miR2Disease, dbDEMC
24	hsa-let-7a	HMDD, miR2Disease, dbDEMC	49	hsa-mir-203	HMDD, miR2Disease, dbDEMC
25	hsa-mir-205	HMDD, miR2Disease, dbDEMC	50	hsa-mir-126	HMDD, miR2Disease, dbDEMC

carcinogenesis,¹¹⁹ which can be used as a diagnostic and prognostic marker for digestive cancers for Asians. These documents were published after the last update date of these three databases, which fully demonstrates the effectiveness of our method.

Discussion and conclusions

miRNA has been found associated with the development of many complex diseases. miRNA imbalance can be regarded as a biomarker for complex disease diagnosis. Although biological experiments can be used to predict disease-related miRNA, it takes much time and lots of efforts to use biological experiments. The calculation method for predicting potential associations between miRNAs and diseases is an effective complement to biological experiments. A reasonable similarity relationship of diseases and miRNAs can improve the prediction accuracy of the calculation method. In order to build a reasonable similarity relationship, we first reconstructed the miRNA network by combining the miRNA family information and the miRNA function similarity, and reconstructed the disease network by using the semantic scores between the known disease and the association information of the miRNA and the disease. Then the global similarity of the two networks is obtained by Laplasse operator. The similarity between diseases and miRNA is measured by global similarity score. Thereafter, the disease-miRNA association network ASm based on the global similarity information of miRNA was constructed by using the global similarity of the miRNA nodes and the

known diseases-miRNA relationship. The disease-miRNA correlation network ASD based on disease global similarity information was constructed by using the global similarity of disease nodes and the known disease-miRNA relationship. Then the consistency information between vectors is obtained by projection of vectors. By using this information to diffuse the disease and miRNA global network respectively, a stable diffusion spectrum was obtained as a corresponding prediction score. Finally, the weighted average of two prediction scores was used as the final score of disease-miRNA association miRNA prediction. This method does not need negative samples and can predict isolated disease and new miRNA. The design of the algorithm is simple. The AUC value of the LOOCV experiment in the gold datum dataset is up to 0.8814, and the AUC value in the forecast data set is up to 0.9512, which is superior to the methods of others. In the case study, we also chose breast tumor and colon tumor for experimental research. Among the top 50 and the corresponding disease related miRNAs predictions, the accuracy rate in the updated HMDD, miR2Disease and dbDEMC databases were 94% and 90% respectively. In the prediction of isolated disease cases, 98% and 94% of the top 50 were confirmed by the three databases mentioned above. Finally, we simulated hsa-mir-21 as a new miRNA for prediction. Of the top 50 diseases predicted, 40 were verified by the database. The rests have found supporting evidence in the latest literature, showing predictive capability of our method.

The algorithm presented in this paper shows strong predictive capability, mainly due to the following reasons. Firstly, we added family information to reconstruct the miRNA similarity



Table 5 The top 50 hsa-mir-21-related diseases candidates predicted by IDNC and the confirmation of these associations

Rank	miRNA name	Evidences	Rank	miRNA name	Evidences
1	Heart failure	HDMM	26	Lymphoma, B-cell	HMDD, miR2Disease
2	Breast neoplasms	HMDD, miR2Disease, dbDEMC	27	Colorectal eoplasms	HMDD, miR2Disease, dbDEMC
3	Lung neoplasms	HMDD, miR2Disease, dbDEMC	28	Hodgkin disease	HMDD, miR2Disease
4	Ovarian neoplasms	HDMM	29	Carcinoma, renal cell	HMDD, miR2Disease, dbDEMC
5	Neoplasms	HDMM	30	Hepatitis, chronic	Unconfirmed
6	Melanoma	HMDD, dbDEMC	31	Lymphoma	HDMM
7	Adrenocortical carcinoma	dbDEMC	32	Azoospermia	Unconfirmed
8	Muscular disorders, atrophic	HDMM	33	Hepatitis C	Unconfirmed
9	Stomach neoplasms	HDMM	34	Lymphoma, primary effusion	dbDEMC
10	Pancreatic neoplasms	HMDD, dbDEMC	35	Sarcoma, kaposi	dbDEMC
11	Lupus vulgaris	HDMM	36	Cardiomyopathy, hypertrophic	HMDD, miR2Disease
12	Colonic neoplasms	HMDD, dbDEMC	37	Pituitary neoplasms	Unconfirmed
13	Autistic disorder	HDMM	38	Uterine cervical neoplasms	HMDD, dbDEMC
14	Prostatic neoplasms	HDMM	39	Waldenstrom macroglobulinemia	Unconfirmed
15	Head and neck neoplasms	HDMM	40	Polycythemia vera	HDMM
16	Carcinoma, hepatocellular	HMDD, miR2Disease, dbDEMC	41	Digestive system neoplasms	Unconfirmed
17	Salivary gland neoplasms	HDMM	42	Urinary bladder neoplasms	HDMM
18	Adenocarcinoma	HDMM	43	Leukemia, B-cell	dbDEMC
19	Schizophrenia	Unconfirmed	44	Leukemia, promyelocytic, acute	dbDEMC
20	Endometriosis	HDMM	45	Precursor B-cell lymphoblastic leukemia-lymphoma	miR2Disease
21	Leukemia, lymphocytic, chronic, B-cell	HMDD, miR2Disease, dbDEMC	46	Retinal neovascularization	Unconfirmed
22	Medulloblastoma	HDMM	47	ACTH-secreting pituitary adenoma	HDMM
23	Leukemia, myeloid, acute	miR2Disease, dbDEMC	48	Neurodegenerative diseases	Unconfirmed
24	Leukemia	HDMM	49	Multiple myeloma	HMDD, dbDEMC
25	Thyroid neoplasms	HMDD, dbDEMC	50	Hepatitis B	Unconfirmed

network, and integrate the known miRNA related disease information and the disease phenotype similarity information to reconstruct the disease network; secondly, we used the Lap-lasse operator to obtain the global similarity of both miRNA network and disease network; thirdly, we reconstructed the disease–miRNA correlation network by adding the global similarity information of the network; the fourth is the use of network consistency to get data association between miRNA and disease. Although the disease-related miRNA prediction model based on IDNC has achieved a satisfactory prediction performance, there are still some defects. Firstly, there are too many parameters. It takes a lot of time to find the best parameter for different data sets; secondly, the construction of disease and miRNA similarity network needs more data to be integrated for accuracy; thirdly, the accuracy of prediction for isolated diseases and new miRNA needs to be improved.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

The research of this paper has been sponsored by National Nature Science Foundation of China (Grant No. 61772192,

61672214, 61672223), Nature Science Foundation of Hunan Province, China (Grant No. 2018JJ2085), Science-Technology of Hunan Province, China(Grant No. 2015GK3029), Science-Technology of Hengyang City, China (Grant No. 2016KJ17, 2012KS19), Major cultivation projects of Hunan Institute of Technology (Grant No. 2017HGPY001).

References

- 1 J. S. Mattick and I. V. Makunin, *Hum. Mol. Genet.*, 2006, **15**, R17–R29.
- 2 G. Meister and T. Tuschi, *Nature*, 2004, **431**, 343.
- 3 D. P. Bartel, *Cell*, 2004, **116**, 281–297.
- 4 V. Ambros, *Cell*, 2001, **107**, 823–826.
- 5 V. Ambros, *Nature*, 2004, **431**, 350.
- 6 L. Zhu, J. Zhao, J. Wang, C. Hu, J. Peng, R. Luo, C. Zhou, J. Liu, J. Lin and Y. Jin, *PLoS Pathog.*, 2016, **12**, e1005423.
- 7 T. R. Fernando, N. I. Rodriguez-Malave and D. S. Rao, *J. Hematol. Oncol.*, 2012, **5**, 7.
- 8 E. A. Miska, *Curr. Opin. Genet. Dev.*, 2005, **15**, 563–568.
- 9 A. M. Cheng, M. W. Byrom, J. Shelton and L. P. Ford, *Nucleic Acids Res.*, 2005, **33**, 1290–1297.
- 10 V. Ambros, *Cell*, 2003, **113**, 673–676.
- 11 P. Xu, M. Guo and B. A. Hay, *Trends Genet.*, 2004, **20**, 617–624.



12 M. Alshalalfa and R. Alhajj, *BMC Bioinf.*, 2013, **14**, S1.

13 D. P. Bartel, *Cell*, 2009, **136**, 215–233.

14 S. Volinia, M. Galasso, S. Costinean, L. Tagliavini, G. Gamberoni, A. Drusco, J. Marchesini, N. Mascellani, M. E. Sana and R. A. Jarour, *Genome Res.*, 2010, **20**, 589–599.

15 L. Yong, Z. Jing, P. Y. Zhang, Z. Yu, S. Y. Sun, S. Y. Yu and Q. S. Xi, *Med. Sci. Monit.*, 2012, **18**, BR299.

16 C. Guo, F. J. Sah, L. Beard, J. K. V. Willson, S. D. Markowitz and K. Guda, *Genes, Chromosomes Cancer*, 2008, **47**, 939–946.

17 B. Shi, L. Sepp-Lorenzino, M. Prisco, P. Linsley and R. Baserga, *J. Biol. Chem.*, 2007, **282**, 32582–32590.

18 A. J. Schetter, S. Y. Leung, J. J. Sohn, K. A. Zanetti, E. D. Bowman, N. Yanaihara, S. T. Yuen, T. L. Chan, D. L. Kwong and G. K. Au, *JAMA, J. Am. Med. Assoc.*, 2008, **299**, 425–436.

19 F. Gao, J. Chang, H. Wang and G. Zhang, *Oncol. Rep.*, 2014, **31**, 351–357.

20 S. M. Johnson, H. Grosshans, J. Shingara, M. Byrom, R. Jarvis, A. Cheng, E. Labourier, K. L. Reinert, D. Brown and F. J. Slack, *Cell*, 2005, **120**, 635–647.

21 C. C. Pritchard, H. H. Cheng and M. Tewari, *Nat. Rev. Genet.*, 2012, **13**, 358.

22 H. Dong, J. Lei, L. Ding, Y. Wen, H. Ju and X. Zhang, *Chem. Rev.*, 2013, **113**, 6207.

23 X. Li, *Bioinformatics*, 2017, **33**, 2829–2836.

24 X. Li, *Curr. Bioinf.*, 2018, **13**, 367–372.

25 M. Lu, Q. Zhang, M. Deng, J. Miao, Y. Guo, W. Gao and Q. Cui, *PLoS One*, 2008, **3**, e3420.

26 S. Bandyopadhyay, R. Mitra, U. Maulik and M. Q. Zhang, *Silence*, 2010, **1**, 6.

27 D. Wang, J. Wang, M. Lu, F. Song and Q. Cui, *Bioinformatics*, 2010, **26**, 1644–1650.

28 X. Chen, L. Y. Wang and L. Huang, *J. Cell. Mol. Med.*, 2018, **22**, 2884–2895.

29 L.-H. Peng, C.-N. Sun, N.-N. Guan, J.-Q. Li and X. Chen, *Mol. Genet. Genomics*, 2018, 1–13.

30 G. Li, J. Luo, Q. Xiao, C. Liang, P. Ding and B. Cao, *IEEE Access*, 2017, **5**, 24032–24039.

31 X. Zeng, X. Zhang and Q. Zou, *Briefings Bioinf.*, 2016, **17**, 193–203.

32 Q. Zou, J. Li, L. Song, X. Zeng and G. Wang, *Briefings Funct. Genomics*, 2016, **15**, 55–64.

33 X. Chen, D. Xie, Q. Zhao and Z.-H. You, *Briefings Bioinf.*, 2017, **10**, 1–25.

34 Q. Jiang, G. Wang, T. Zhang and Y. Wang, Predicting human microRNA-disease associations based on support vector machine, in *2010 IEEE International Conference On Bioinformatics and Biomedicine (BIBM)*, 2010, pp. 467–472.

35 J. Xu, C.-X. Li, J.-Y. Lv, Y.-S. Li, Y. Xiao, T.-T. Shao, X. Huo, X. Li, Y. Zou and Q.-L. Han, *Mol. Cancer Ther.*, 2011, **10**, 1857–1866.

36 X. Zeng, Z. Xuan, Y. Liao and L. Pan, *Biochim. Biophys. Acta*, 2016, **1860**, 2735–2739.

37 X. Chen and G.-Y. Yan, *Sci. Rep.*, 2014, **4**, 5501.

38 X. Chen and L. Huang, *PLoS Comput. Biol.*, 2017, **13**, e1005912.

39 L. Peng, M. Peng, B. Liao, Q. Xiao, W. Liu, G. Huang and K. Li, *RSC Adv.*, 2017, **7**, 44447–44455.

40 X. Chen, Y. W. Niu, G. H. Wang and G. Y. Yan, *J. Transl. Med.*, 2017, **15**, 251.

41 J. Luo, Q. Xiao, C. Liang and P. Ding, *IEEE Access*, 2017, **5**, 2503–2513.

42 G. Li, J. Luo, Q. Xiao, C. Liang and P. Ding, *RSC Adv.*, 2018, **8**, 4377–4385.

43 W. Lan, J. Wang, M. Li, J. Liu, F. X. Wu and Y. Pan, *IEEE/ACM Trans. Comput. Biol. Bioinf.*, 2016, **1**.

44 W. Lan, J. Wang, M. Li, J. Liu and Y. Pan, Predicting microRNA-disease associations by integrating multiple biological information, in *IEEE International Conference on Bioinformatics and Biomedicine*, 2015, pp. 183–188.

45 Q. Xiao, J. Luo, C. Liang, J. Cai and P. Ding, *Bioinformatics*, 2018, **34**, 239–248.

46 Y. Zhong, P. Xuan, X. Wang, T. Zhang, J. Li, Y. Liu and W. Zhang, *Bioinformatics*, 2018, **34**, 267–277.

47 X. Chen, J. Yin, J. Qu and L. Huang, *PLoS Comput. Biol.*, 2018, **14**, e1006418.

48 X. Chen, L. Huang, D. Xie and Q. Zhao, *Cell Death Dis.*, 2018, **9**, 3.

49 X. Chen, Y. Gong, D. H. Zhang, Z. H. You and Z. W. Li, *J. Cell. Mol. Med.*, 2018, **22**, 472–485.

50 L. Fu and Q. Peng, *Sci. Rep.*, 2017, **7**, 14482.

51 X. Chen, C. C. Yan, X. Zhang, Z. Li, L. Deng, Y. Zhang and Q. Dai, *Sci. Rep.*, 2015, **5**, 13877.

52 J. Luo, P. Ding, L. Cheng, B. Cao and X. Chen, *IEEE/ACM Trans. Comput. Biol. Bioinf.*, 2017, **14**, 7.

53 X. Zeng, N. Ding, A. Rodríguez-Patón, Z. Lin and Y. Ju, *Curr. Proteomics*, 2016, **13**, 151–157.

54 J. Q. Li, Z. H. Rong, X. Chen, G. Y. Yan and Z. H. You, *Oncotarget*, 2017, **8**, 21187–21199.

55 L. Peng, M. Peng, B. Liao, G. Huang, W. Liang and K. Li, *Sci. Rep.*, 2017, **7**, 6007.

56 X. Chen, L. Wang, J. Qu, N.-N. Guan and J.-Q. Li, *Bioinformatics*, 2018, **2**, 503.

57 Y. Zhao, X. Chen and J. Yin, *Front. Genet.*, 2018, **9**, 324.

58 X. Chen, D. Xie, L. Wang, Q. Zhao, Z.-H. You and H. Liu, *Bioinformatics*, 2018, **1**, 9.

59 J. Li, Z. Wu, F. Cheng, W. Li, G. Liu and Y. Tang, *Sci. Rep.*, 2014, **4**, 5576.

60 C. Gu, B. Liao, X. Li, L. Cai, H. Chen, K. Li and J. Yang, *RSC Adv.*, 2017, **7**, 44961–44971.

61 L. Peng, Y. Chen, N. Ma and X. Chen, *Mol. BioSyst.*, 2017, 2650–2659.

62 X. Chen, Y. W. Niu, G. H. Wang and G. Y. Yan, *J. Biomed. Inf.*, 2017, **76**, 50–58.

63 Q. Zou, J. Li, Q. Hong, Z. Lin, Y. Wu, H. Shi and Y. Ju, *BioMed Res. Int.*, 2015, **2015**, 810514.

64 X. Chen, Z. Zhou and Y. Zhao, *RNA Biology*, 2018, 1–50.

65 Q. Jiang, Y. Hao, G. Wang, L. Juan, T. Zhang, M. Teng, Y. Liu and Y. Wang, *BMC Syst. Biol.*, 2010, **4**(suppl. 1), S2.

66 Q. Jiang, G. Wang and Y. Wang, An approach for prioritizing disease-related microRNAs based on genomic data integration, in *International Conference on Biomedical Engineering and Informatics*, 2010, pp. 2270–2274.





67 X. Li, Q. Wang, Y. Zheng, S. Lv, S. Ning, J. Sun, T. Huang, Q. Zheng, H. Ren and J. Xu, *Nucleic Acids Res.*, 2011, **39**, e153.

68 H. Shi, J. Xu, G. Zhang, L. Xu, C. Li, L. Wang, Z. Zhao, W. Jiang, Z. Guo and X. Li, *BMC Syst. Biol.*, 2013, **7**, 101.

69 C. Xu, Y. Ping, X. Li, H. Zhao, L. Wang, H. Fan, Y. Xiao and X. Li, *Mol. BioSyst.*, 2014, **10**, 2800–2809.

70 S. Rossi, A. Tsirigos, A. Amoroso, N. Mascellani, I. Rigoutsos, G. A. Calin and S. Volinia, *Genomics*, 2011, **97**, 71–76.

71 P. Xuan, K. Han, M. Guo, Y. Guo, J. Li, J. Ding, Y. Liu, Q. Dai, J. Li and Z. Teng, *PLoS One*, 2013, **8**, e70204.

72 X. Chen, Q. F. Wu and G. Y. Yan, *RNA Biology*, 2017, **1**.

73 D. H. Le, *Comput. Biol. Chem.*, 2015, **58**, 139–148.

74 X. Chen, M.-X. Liu and G.-Y. Yan, *Mol. BioSyst.*, 2012, **8**, 2792–2798.

75 H. Shi, G. Zhang, M. Zhou, C. Liang, H. Yang, J. Wang, J. Sun and Z. Wang, *PLoS One*, 2016, **11**, e0148521.

76 P. Xuan, K. Han, Y. Guo, J. Li, X. Li, Y. Zhong, Z. Zhang and J. Ding, *Bioinformatics*, 2015, **31**, 1805–1815.

77 B. Liao, S. Ding, H. Chen, Z. Li and L. Cai, *J. Bioinf. Comput. Biol.*, 2015, **13**, 1550014.

78 J. Luo and Q. Xiao, *J. Biomed. Inf.*, 2017, **66**, 194–203.

79 I. Mugunga, Y. Ju, X. Liu and X. Huang, *Oncotarget*, 2017, **8**, 58526–58535.

80 H. Chen and Z. Zhang, *BMC Med. Genomics*, 2013, **6**, 12.

81 C. Gu, L. Bo, X. Li and K. Li, *Sci. Rep.*, 2016, **6**, 36054.

82 X. Li, Y. Lin and C. Gu, *RSC Adv.*, 2017, **7**, 32216–32224.

83 J. J. Nalluri, B. K. Kamapantula, D. Barh, N. Jain, A. Bhattacharya, S. S. de Almeida, R. T. Juca Ramos, A. Silva, V. Azevedo and P. Ghosh, *BMC Genomics*, 2015, **16**, S12.

84 X. Chen, C. C. Yan, Z. Xu, Z. H. You, H. Yuan and G. Y. Yan, *Oncotarget*, 2016, **7**, 65257–65269.

85 Z. H. You, Z. A. Huang, Z. Zhu, G. Y. Yan, Z. W. Li, Z. Wen and X. Chen, *PLoS Comput. Biol.*, 2017, **13**, e1005455.

86 D. Sun, A. Li, H. Feng and M. Wang, *Mol. BioSyst.*, 2016, **12**, 2224.

87 X. Chen and J. Qu, *Front. Genet.*, 2018, **9**, 234.

88 X. Chen, J.-R. Yang, N.-N. Guan and J.-Q. Li, *Frontiers in Physiology*, 2018, **9**, 92.

89 X. Chen, C. C. Yan, X. Zhang, Z. H. You, L. Deng, Y. Liu, Y. Zhang and Q. Dai, *Sci. Rep.*, 2016, **6**, 21106.

90 X. Chen, N. Guan, J. Li and G. Yan, *J. Cell. Mol. Med.*, 2017, 1548–1561.

91 X. Chen, Z. C. Jiang, D. Xie, D. S. Huang, Q. Zhao, G. Y. Yan and Z. H. You, *Mol. BioSyst.*, 2017, **13**, 1202–1212.

92 G. Li, J. Luo, Q. Xiao, C. Liang and P. Ding, *J. Biomed. Inf.*, 2018, **82**, 169–177.

93 X. Chen, M. X. Liu and G. Y. Yan, *Mol. BioSyst.*, 2012, **8**, 2792–2798.

94 C. Gu, B. Liao, X. Li and K. Li, *Sci. Rep.*, 2016, **6**, 36054.

95 M. Chen, X. Lu, B. Liao, Z. Li, L. Cai and C. Gu, *PLoS One*, 2016, **11**, e0166509.

96 M. A. Van Driel, J. Bruggeman, G. Vriend, H. G. Brunner and J. A. Leunissen, *Eur. J. Hum. Genet.*, 2006, **14**, 535.

97 A. Kozomara and S. Griffiths Jones, *Nucleic Acids Res.*, 2011, **39**, D152–D157.

98 D. Zhou, O. Bousquet, T. N. Lal, J. Weston, and B. Schölkopf, Learning with local and global consistency, in *Advances in neural information processing systems*, 2004, pp. 321–328.

99 H. Chen and Z. Zhang, *BMC Med. Genomics*, 2013, **6**, 12.

100 R. L. Siegel, K. D. Miller, S. A. Fedewa, D. J. Ahnen, R. G. Meester, A. Barzi and A. Jemal, *Ca-Cancer J. Clin.*, 2017, **67**, 177.

101 R. Nonaka, J. Nishimura, Y. Kagawa, H. Osawa, J. Hasegawa, K. Murata, S. Okamura, H. Ota, M. Uemura and T. Hata, *Oncol. Rep.*, 2014, **32**, 2354–2358.

102 P. Mussnich, R. Ros, R. Bianco, A. Fusco and D. D'Angelo, *Expert Opin. Ther. Targets*, 2015, **19**, 1017–1026.

103 Y. Niu, Y. Wu, J. Huang, Q. Li, K. Kang, J. Qu, F. Li and D. Gou, *Sci. Rep.*, 2016, **6**, 35611.

104 M. Pichler, A. L. Ress, E. Winter, V. Stieglbauer, M. Karbriener, D. Schwarzenbacher, M. Scheideler, C. Ivan, S. W. Jahn and T. Kiesslich, *Br. J. Cancer*, 2014, **110**, 1614–1621.

105 T. Tanaka, M. Arai, S. Wu, T. Kanda, H. Miyauchi, F. Imazeki, H. Matsubara and O. Yokosuka, *Oncol. Rep.*, 2011, **26**, 1329.

106 H. Persson, A. Kvist, N. Rego, J. Staaf, J. Vallon-Christersson, L. Luts, N. Loman, G. Jonsson, H. Naya and M. Hoglund, *Cancer Res.*, 2011, **71**, 78–86.

107 J. Shou, S. Gu and W. Gu, *Exp. Ther. Med.*, 2015, **9**, 167–171.

108 C. Cai, H. Ashktorab, X. Pang, Y. Zhao, W. Sha, Y. Liu and X. Gu, *PLoS One*, 2012, **7**, e29750.

109 L. Yang, X. Q. Tang, Z. Bai and X. Dai, *Sci. Rep.*, 2016, **6**, 35773.

110 Z. Han, F. Chen, X. Ge, J. Tan, P. Lei and J. Zhang, *Brain Res.*, 2014, **1582**, 12.

111 E. Montalban, N. Mattugini, R. Ciarapica, C. Provenzano, M. Savino, F. Scagnoli, G. Prosperini, C. Carissimi, V. Fulci and C. Matrone, *NeuroMol. Med.*, 2014, **16**, 415–430.

112 K. Smigelska-Czepiel, d. B. A. Van, P. Jellema, I. Slezak-Prochazka, H. Maat, d. B. H. Van, V. D. L. Rj, J. Kluiver, E. Brouwer and A. M. Boots, *PLoS One*, 2013, **8**, e76217.

113 Z. Zhang, Y. Zha, W. Hu, Z. Huang, Z. Gao, Y. Zang, J. Chen, L. Dong and J. Zhang, *J. Biol. Chem.*, 2013, **288**, 37082.

114 W. Ding, J. Xin, L. Jiang, Q. Zhou, T. Wu, D. Shi, B. Lin, L. Li and J. Li, *Sci. Rep.*, 2015, **5**, 13098.

115 Q. Liao, P. Han, Y. Huang, Z. Wu, Q. Chen, S. Li, J. Ye and X. Wu, *PLoS One*, 2015, **10**, e0130677.

116 C. Yao, Q. Yuan, M. Niu, H. Fu, F. Zhou, W. Zhang, H. Wang, L. Wen, L. Wu and Z. Li, *Mol. Ther.-Nucleic Acids*, 2017, **9**, 182–194.

117 D. R. Gutsaeva, M. Thounaojam, S. Rajpurohit, F. L. Powell, P. M. Martin, S. Goei, M. Duncan and M. Bartoli, *Oncotarget*, 2017, **8**, 103568–103580.

118 H. Andrade, M. Albuquerque, T. Peluzzo, D. Dogni, A. Nucci, I. Lopes-Cendes, M. Franca Jr and S. Avansini, *Neurology*, 2015, 84.

119 C. Yin, X. Zhou, Y. Dang, Y. Jin and G. Zhang, *Medicine*, 2015, **94**, e2123.